SOX 9 Antibody Monoclonal

<strong>SOX 9 Antibody Monoclonal </strong>_x000D_ <strong>Catalog number:</strong> B2010549_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 uL_x000D_ <strong>Molecular Weight or Concentration:</strong> 150 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool in various immunoapplications related to human transcription factor SOX-9_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> Transcription factor SOX-9, Anti-SOX 9 antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Ko JY, Lee J, Lee J, Ryu YH, Im GI. <i>SOX</i>-<i>6</i>, <i>9</i>-Transfected_x000D_ Adipose Stem Cells to Treat Surgically-Induced Osteoarthritis in Goats. Tissue_x000D_ Eng Part A. 2019 Jul;25(13-14):990-1000._x000D_ _x000D_ 2: Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu_x000D_ Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and_x000D_ efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in_x000D_ patients with previously untreated, unresectable, advanced, or recurrent_x000D_ gastric/gastroesophageal junction cancer: interim results of a randomized, phase_x000D_ II trial (ATTRACTION-4). Ann Oncol. 2019 Feb 1;30(2):250-258._x000D_ _x000D_ 3: Zhang Y, Huang X, Yuan Y. Anti-inflammatory capacity of Apremilast in human_x000D_ chondrocytes is dependent on SOX-9. Inflamm Res. 2020 Nov;69(11):1123-1132._x000D_ _x000D_ 4: Raftery RM, Gonzalez Vazquez AG, Chen G, O'Brien FJ. Activation of the SOX-5,_x000D_ SOX-6, and SOX-9 Trio of Transcription Factors Using a Gene-Activated Scaffold_x000D_ Stimulates Mesenchymal Stromal Cell Chondrogenesis and Inhibits Endochondral_x000D_ Ossification. Adv Healthc Mater. 2020 May;9(10):e1901827._x000D_ _x000D_ 5: Ball HC, Ansari MY, Ahmad N, Novak K, Haqqi TM. A retrotransposon gag-like-3_x000D_ gene RTL3 and SOX-9 co-regulate the expression of COL2A1 in chondrocytes._x000D_ Connect Tissue Res. 2020 Oct 12:1-14._x000D_ _x000D_ 6: Allison S. A SOX-9-NAV3-YAP1 axis in kidney fibrosis. Nat Rev Nephrol. 2021_x000D_ May;17(5):297._x000D_ _x000D_ 7: Yang Z, Huang CY, Candiotti KA, Zeng X, Yuan T, Li J, Yu H, Abdi S. Sox-9_x000D_ facilitates differentiation of adipose tissue-derived stem cells into a_x000D_ chondrocyte-like phenotype in vitro. J Orthop Res. 2011 Aug;29(8):1291-7._x000D_ _x000D_ 8: Wang S, Li C, Yu Y, Qiao J. Decreased expression of microRNA-145 promotes the_x000D_ biological functions of fibroblasts in hypertrophic scar tissues by upregulating_x000D_ the expression of transcription factor SOX-9. Exp Ther Med. 2019_x000D_ Nov;18(5):3450-3460._x000D_ _x000D_ 9: Wu SC, Chen CH, Wang JY, Lin YS, Chang JK, Ho ML. Hyaluronan size alters_x000D_ chondrogenesis of adipose-derived stem cells via the CD44/ERK/SOX-9 pathway._x000D_ Acta Biomater. 2018 Jan 15;66:224-237._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/25316259/">10: Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T,_x000D_ Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H,_x000D_ Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase_x000D_ III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in_x000D_ chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015_x000D_ Jan;26(1):141-148. </a>_x000D_ _x000D_ <strong>Products Related to SOX 9 Antibody Monoclonal</strong><a href="https://moleculardepot.com/product-category/Antibodies/">: Antibodies</a>